A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Trametinib (Primary) ; Iodine-124; Iodine-131
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 19 Aug 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Jul 2021.
- 17 Dec 2018 Planned primary completion date changed from 1 Nov 2018 to 31 Jul 2019.
- 31 Aug 2018 Biomarkers information updated